Hengrui Pharma(SH:600276) Zheng Quan Ri Bao Wang·2025-11-13 11:49Core Insights - The discussion at the Shanghai Stock Exchange International Investor Conference focused on the globalization of Chinese pharmaceutical companies and their strategies for international expansion [1] Group 1: Company Strategies for Globalization - Aopumai's chairman emphasized the importance of maintaining core business and pursuing mergers and acquisitions to enhance international competitiveness [2] - Aopumai is currently in the process of merging with Pengli Bio, which will strengthen its capabilities in preclinical drug efficacy evaluation and pharmacokinetics [2] - Aopumai has established a 1 billion yuan biomanufacturing industry fund to support the development of its industrial ecosystem [2] Group 2: Innovation and Market Position - Jiangsu Hengrui Medicine ranks second in the global innovative drug pipeline, indicating significant progress in Chinese pharmaceutical innovation [3] - Hengrui aims to achieve commercial sales of 1 billion to 2 billion USD from innovative drugs in international markets within the next 15 years to be considered a "world-class" pharmaceutical company [3] Group 3: Diverse Internationalization Approaches - Aotai Bio's chairman highlighted the differences between the medical device and innovative drug sectors, noting that the latter experiences frequent ranking changes while the former has a more stable market structure [4] - Hengrui's global strategy includes exploring various internationalization models such as licensing, joint ventures, and independent development [5] Group 4: Talent and Market Adaptation - The executives agreed on the importance of attracting high-end talent and creating a mature platform for both domestic and international professionals [6] - Aopumai's strategy involves investing in local markets while seeking strategic partnerships with international platforms to build brand recognition [6]